Mutational and secondary structural analysis of the basolateral sorting signal of the polymeric immunoglobulin receptor.

The 17-juxtamembrane cytoplasmic residues of the polymeric immunoglobulin receptor contain an autonomous basolateral targeting signal that does not mediate rapid endocytosis (Casanova, J. E., G. Apodaca, and K. E. Mostov. Cell. 66:65-75). Alanine-scanning mutagenesis identifies three residues in this region, His656, Arg657, and Val660, that are most essential for basolateral sorting and two residues, Arg655 and Tyr668, that play a lesser role in this process. Progressive truncations suggested that Ser664 and Ile665 might also play a role in basolateral sorting. However, mutation of these residues to Ala or internal deletions of these residues did not affect basolateral sorting, indicating that these residues are probably not required for basolateral sorting. Two-dimensional NMR spectroscopy of a peptide corresponding to the 17-mer signal indicates that the sequence Arg658-Asn-Val-Asp661 has a propensity to adopt a beta-turn in solution. Residues COOH-terminal to the beta-turn (Arg662 to Arg669) seem to take up a nascent helix structure in solution. Substitution of Val660 with Ala destabilizes the turn, while mutation of Arg657 to Ala does not appear to affect the turn structure. Neither mutation detectably altered the stability of the nascent helix in the COOH-terminal portion of the peptide

DeepSig: Deep learning improves signal peptide detection in proteins

Motivation: The identification of signal peptides in protein sequences is an important step toward protein localization and function characterization. Results: Here, we present DeepSig, an improved approach for signal peptide detection and cleavage-site prediction based on deep learning methods. Comparative benchmarks performed on an updated independent dataset of proteins show that DeepSig is the current best performing method, scoring better than other available state-of-the-art approaches on both signal peptide detection and precise cleavage-site identification. Availability and implementation: DeepSig is available as both standalone program and web server at https://deepsig.biocomp.unibo.it. All datasets used in this study can be obtained from the same website

Method of Detecting and Targeting Mutations in Cancer

While there are many differences between tumor and non-tumor cells, the basic underlying distinction is in the DNA. Tumor cells harbor mutations, at least some of which are not present in non-tumor cells. Thus, a method of directly targeting cells containing specific mutations has potential for detection or treatment of cancer without the toxicity associated with more indirect approaches. Also, as mutations are a necessary component of malignancy, such a method is potentially applicable to all tumors. 

I propose a method by which several recently developed techniques can be utilized in a novel way to accomplish the goal of directly targeting mutations for cancer detection and therapy. The model can be summarized as follows: (1) Determine potential target mutations present in tumor cells but not non-tumor cells. (2) Construct molecules that will bind to DNA at the sites of mutation, but will not bind to DNA in normal cells. And, as a consequence of the molecules binding to the mutation, the cells will be destroyed. (3) Deliver these molecules to all cells (or at least all tumor cells). I hypothesize that such molecules can now be constructed using sequence-specific DNA binding proteins (such as customized zinc-finger DNA binding proteins) fused to transcriptional activator domains (such as VP16) and reporter or toxin genes. The necessary genes can be linked to the DNA binding proteins utilizing a recently described method based on expressed protein ligation. 
&#xa

Structural and biophysical analysis of important biomedical enzymes and nano-architectures

Dopa decarboxylase (DDC) is an important enzyme in the catecholamine biosynthesis pathways. Catecholamines, e.g., dopamine, serotonin, etc. often are the major neuromodulators or neurotransmitters. Hence, DDC plays a key role in regulation of neurodegenerative diseases like Parkinson’s disease (PD). In order to achieve a medicine for PD, a successful inhibitor for DDC, that could reduce the activity of DDC in the blood while making it more effective in brain, is required. An effective design of an inhibitor requires a detailed structural study of human DDC. It was aimed to solve the DDC structure by X-ray crystallography. In order to have enough protein the DDC encoding gene has been cloned in the pET21d vector which was later termed as pET-DDC-His. However, it required numerous trials and errors until a suitable condition for soluble DDC expression was found. Addition of additives like PLP, ethanol, a complex of sorbitol and betaine in the growth medium of the bacteria did not help bring the protein in the soluble part as it formed inclusion bodies. Several soluble protein fusions with DDC, like Thioredoxin and Glutathione-S-transferase were also not quite helpful towards achieving soluble expression of DDC. Finally, a coexpression of DDC along with bacterial chaperone proteins, e.g., GroEL and GroES (after cotransforming both the DDC and Chaperone protein encoding plasmid in the same E.coli cell, used for expression) lead to solubilization of recombinant human DDC. This enzyme was then purified to homogeneity by successively passing the crude bacterial proteins through Ni-chelate-affinity chromatography and Size Exclusion Chromatography. The purified protein (>90 % purity) did not produce a good yield (4mg/ 8L culture), but this was enough to start the initial crystallization trial. Using a scale up to a 50 L culture, quite a good amount of protein was achieved. The homogeneity of DDC was further confirmed by using Multi-Angle Light Scattering and Blue Native PAGE. The dimeric enzyme preparation was then utilized for crystallization using the Hanging Drop Vapor Diffusion method. In a particular condition of the crystal screens trigonal bipyramidal crystals formed. However, these crystals did not show good diffraction when bombarded with X-ray beams. Later, this particular crystallization condition remained irreproducible. The peptide nanoparticle, designed and produced in our lab, could possibly be a very valuable tool in biomedical applications, e.g., in designing vaccines, delivering drugs, bioimaging, serodiagnosis, etc. The design of the peptide nanoparticles is based on the application of the symmetry elements of virus icosahedral capsid on a specially designed building block peptide. The designed peptide building block contains two oligomerization motifs, i.e., a trimeric coiled coil and a pentameric coiled coil joined by a linker region. Sixty such peptide units, upon self-assembly, would produce peptide nanoparticle mimicking a small icosahedral virus particle. The peptide chains in the building block provide flexibility in the design so that an additional peptide could be attached to it at the C-terminus in order to functionalize the peptide nanoparticle for various biomedical applications. First of all, the functional peptide at the C-terminus could be an epitope for the antibody of a life threatening disease like HIV. These peptide nanoparticles can then function as the potent vaccine candidate for that particular disease. In this thesis work, I have attached the two epitopes against the two broadly neutralizing classes of antibody for HIV infection, 2F5 and 4E10, to the peptide nanoparticle. Secondly, another sequence of peptide, which proved to have the capacity of seeding gold on its surface, was attached to the building block peptide unit. The nanoparticle, functionalized with such a peptide, can decorate a gold layer surrounding it. Gold coating on the peptide nanoparticle scaffold can provide a nanostructure, called ‘nanoshells’, which could be very important in the field of therapeutics because of its ability in easy detection and quick treatment of cancer cells. Lastly, I added three peptides; those are recognized in the culture filtrates of M.tuberculosis isolated from TB patients, separately, to the basic peptide construct to form three different nanoparticles. Also, I tried to make a single nanoparticle that displays all the three peptides on its surface. Such a nanoparticle could be a very useful tool in the serodiagnosis or the antibody-based rapid detection of the deadly disease- Tuberculosis. The nanoparticle formation in each of the above-mentioned cases was more or less successful. One of the constructs could successfully even produce gold shells on the peptide nanoparticle

Seprase: An overview of an important matrix serine protease

Seprase or Fibroblast Activation Protein (FAP) is an integral membrane serine peptidase, which has been shown to have gelatinase activity. Seprase has a dual function in tumour progression. The proteolytic activity of Seprase has been shown to promote cell invasiveness towards the ECM and also to support tumour growth and proliferation. Seprase appears to act as a proteolytically active 170-kDa dimer, consisting of two 97- kDa subunits. It is a member of the group type II integral serine proteases, which includes dipeptidyl peptidase IV (DPPIV/CD26) and related type II transmembrane prolyl serine peptidases, which exert their mechanisms of action on the cell surface. DPPIV and Seprase exhibit multiple functions due to their abilities to form complexes with each other and to interact with other membrane-associated molecules. Localisation of these protease complexes at cell surface protrusions, called invadopodia, may have a prominent role in processing soluble factors and in the degradation of extracellular matrix components that are essential to the cellular migration and matrix invasion that occur during tumour invasion, metastasis and angiogenesis

Phosphorylation of nuclear Tau is modulated by distinct cellular pathways

Post-translational protein modification controls the function of Tau as a scaffold protein linking a variety of molecular partners. This is most studied in the context of microtubules, where Tau regulates their stability as well as the distribution of cellular components to defined compartments. However, Tau is also located in the cell nucleus; and is found to protect DNA. Quantitative assessment of Tau modification in the nucleus when compared to the cytosol may elucidate how subcellular distribution and function of Tau is regulated. We undertook an unbiased approach by combing bimolecular fluorescent complementation and mass spectrometry in order to show that Tau phosphorylation at specific residues is increased in the nucleus of proliferating pluripotent neuronal C17.2 and neuroblastoma\ua0SY5Y cells. These findings were validated with the use of nuclear targeted Tau and subcellular fractionation, in particular for the phosphorylation at T181, T212 and S404. We also report that the DNA damaging drug Etoposide increases the translocation of Tau to the nucleus whilst reducing its phosphorylation. We propose that overt phosphorylation of Tau, a hallmark of neurodegenerative disorders defined as tauopathies, may negatively regulate the function of nuclear Tau in protecting against DNA damage